At INAR, we carry out feasibility studies to identify crucial information necessary for proper preparation of HTA analyses, allowing Companies to make optimal managerial decisions related to the assessed drug. Such studies contain the following:

• A review of up-to-date guidelines and clinical recommendations used to identify potential comparators;
• A review of public funding recommendations and decisions for a given intervention;
• Identification of crucial clinical trials and their results based on secondary sources;
• Summary of the most relevant clinical trials;
• Initial formulation of the clinical questions derived from the PICOS scheme;
• Recommendations in regard to assumptions of clinical analysis (analysis based on H2H comparison vs need for indirect comparisons or MTC);
• A review of economic analyses for a given intervention to indicate potential threats or challenges for development of cost-effectiveness analysis;
• Gathering epidemiologic data for a preliminarily estimated target population.

The range of activities in the evaluation of the feasibility of the HTA report can be adapted to a Company’s needs. The results of a feasibility study and discussions on further steps are presented to the Company.